Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02870205 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
A Phase 3 study, sponsored by Glenmark Specialty S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,176
- Enrollment target
NCT02870205: Completed Phase 3 study, sponsored by Glenmark Specialty S.A..
NCT02870205 is a Phase 3 study that has completed, run by Glenmark Specialty S.A.. The registered enrollment target is 1,176 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02870205, a Phase 3 study, has completed, sponsored by Glenmark Specialty S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,176 participants
- Enrollment target
Study Summary
Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis (subjects 12 years of age and older)
Primary Outcome
The Reflective Total Nasal Symptom Score (rTNSS) was assessed by 12-hour reflective scoring of the severity of four nasal symptoms (rhinorrhea, sneezing, nasal congestion, nasal itching). Symptom scores ranged from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerat
Interventions
- DRUG GSP 301 NS
- DRUG GOM-NS
- DRUG GMM-2 NS
- DRUG GSP 301 placebo NS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,176 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
What the finished NCT02870205 record still lists
NCT02870205 is an interventional study that assigns participants to a tested intervention. Its 1,176 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 4 interventions - of which GSP 301 NS is the first listed.
NCT02870205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02870205 about?
NCT02870205 is a clinical study titled "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)". Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis (subjects 12 years of age and older)
What is the current status of trial NCT02870205?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,176 participants. The study started on 2016-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02870205?
The interventions under investigation include: GSP 301 NS (DRUG), GOM-NS (DRUG), GMM-2 NS (DRUG), GSP 301 placebo NS (DRUG).
Who is sponsoring clinical trial NCT02870205?
This trial is sponsored by Glenmark Specialty S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02870205's enrollment target sits among peer trials
1,176 235th of 2000 higher than 1,766 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia